Mainstream

Regeneron outlines path to $17B Dupixent annual sales and initiates 10 Lynozyfic registrational trials amid robust Q2 growth

Regeneron outlines path to $17B Dupixent annual sales and initiates 10 Lynozyfic registrational trials amid robust Q2 growth

Post ContentregnRead More

You might also be interested in reading Stock market today: here’s why the Dow Jones is crashing.

August 1, 2025
In Mainstream